Eucrates Biomedical Acquisition Corp. financial data

Industry
Blank Checks
Location
250 West 55 Th Street, Suite 13 D, New York, NY
State of incorporation
Virgin Islands, British
Fiscal year end
December 31
Latest financial report
10-K - Q4 2022 - Apr 13, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 138 %
Debt-to-equity -107 % +2.35%
Return On Equity -62.8 % -3.63%
Return On Assets 2.95 % -18.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4.21M shares -68.7%
Common Stock, Shares, Outstanding 2.98M shares 0%
Entity Public Float 107M USD

Income Statement

Label TTM Value / Value Unit Change %
Operating Income (Loss) -699K USD +5.99%
Nonoperating Income (Expense) 3.12M USD -31.7%
Net Income (Loss) Attributable to Parent 2.42M USD -36.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current 132K USD -50%
Assets 12.5M USD -88.1%
Accrued Liabilities, Current 5.08K USD -86.8%
Liabilities, Current 65.1K USD +69.4%
Liabilities 3.95M USD -31.9%
Retained Earnings (Accumulated Deficit) -3.72M USD +32.3%
Stockholders' Equity Attributable to Parent -3.72M USD +32.3%
Liabilities and Equity 12.5M USD -88.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -140K USD -29.7%
Net Cash Provided by (Used in) Financing Activities 250K USD
Common Stock, Shares, Issued 2.98M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 110K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 18.9K USD -61.6%
Preferred Stock, Shares Issued 0 shares
Unrecognized Tax Benefits 0 USD
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 0 USD/shares